<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638103</url>
  </required_header>
  <id_info>
    <org_study_id>TV48125-CNS-30051</org_study_id>
    <secondary_id>2015-004550-18</secondary_id>
    <nct_id>NCT02638103</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine</brief_title>
  <acronym>HALO</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous (SC)
      administration of TEV-48125 in adult participants with chronic migraine (CM) or episodic
      migraine (EM). Participants with CM or EM who complete the pivotal efficacy studies of
      TEV-48125 (TV48125-CNS-30049 [NCT02621931] and TV48125-CNS-30050 [NCT02629861]) and agree to
      participate in this study; and new participants meeting eligibility criteria (not rolling
      over from pivotal studies), will be enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 26, 2016</start_date>
  <completion_date type="Actual">December 8, 2018</completion_date>
  <primary_completion_date type="Actual">June 6, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline (Day 0) up to follow-up visit (Day 533)</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE was defined as inability to carry out usual activities. Treatment-related AEs were defined as AEs with possible, probable, definite, or missing relationship to study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results</measure>
    <time_frame>Baseline (Day 0) up to end of treatment (EOT) visit (Day 336)</time_frame>
    <description>Potentially clinically significant abnormal serum chemistry findings included: Blood Urea Nitrogen (BUN): greater than or equal to (&gt;=) 10.71 millimoles/liter (mmol/L), creatinine: &gt;=177 micromoles/liter (µmol/L), bilirubin: &gt;=34.2 µmol/L, Alanine Aminotransferase (ALT) (units/liter [U/L]): &gt;=3*upper limit of normal (ULN) Aspartate Aminotransferase (AST) (U/L): &gt;=3*ULN, and Gamma Glutamyl Transferase (GGT) (U/L): &gt;=3*ULN. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Abnormal Hematology Results</measure>
    <time_frame>Baseline (Day 0) up to EOT visit (Day 336)</time_frame>
    <description>Potentially clinically significant abnormal hematology findings included: hemoglobin: less than (&lt;) 115 grams/liter (g/L) (in males) or less than or equal to (&lt;=) 95 g/L (in females), hematocrit: &lt;0.37 L/L (in male) or &lt;0.32 L/L (in female), leukocytes: &gt;=20*10^9/L or &lt;=3*10^9/L, eosinophils/leukocytes: &gt;=10%, and platelets: &gt;=700*10^9/L or &lt;=75*10^9/L. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results</measure>
    <time_frame>Baseline (Day 0) up to EOT visit (Day 336)</time_frame>
    <description>Potentially clinically significant abnormal urinalysis findings included: blood: &gt;=2 unit increase from baseline, urine glucose (milligrams/decilitre [mg/dL]): &gt;=2 unit increase from baseline, ketones (mg/dL): &gt;=2 unit increase from baseline, urine protein (mg/dL): &gt;=2 unit increase from baseline. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values</measure>
    <time_frame>Baseline (Day 0) up to EOT visit (Day 336)</time_frame>
    <description>Potentially clinically significant abnormal vital signs findings included: pulse rate: &lt;=50 beats/minute (bpm) and decrease of &gt;=15 bpm, or &gt;=120 bpm and increase of &gt;=15 bpm; systolic blood pressure: &lt;=90 millimeters of mercury (mmHg) and decrease of &gt;=20 mmHg, or &gt;=180 mmHg and increase of &gt;=20 mmHg; diastolic blood pressure: &lt;=50 mmHg and decrease of &gt;=15 mmHg or &gt;=105 mmHg and increase of &gt;=15 mmHg; respiratory rate: &lt;10 breaths/minute; and body temperature &gt;=38.3 degrees centigrade and change of &gt;=1.1 degrees centigrade. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters</measure>
    <time_frame>Baseline (Day 0), endpoint (Day 336)</time_frame>
    <description>ECG parameters included: heart rate, PR interval, QRS interval, QT interval corrected using the Fridericia formula (QTcF), QT interval corrected using the Bazett's formula (QTcB) and RR interval. Shifts represented as Baseline - endpoint value (last observed post-baseline value). Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Shift From Baseline to Endpoint in Coagulation Laboratory Test Results</measure>
    <time_frame>Baseline (Day 0), endpoint (Day 336)</time_frame>
    <description>Coagulation parameters included: prothrombin time (PT) (seconds), prothrombin international normalized ratio (INR), activated partial thromboplastin time (aPTT) (seconds). Shifts represented as Baseline - endpoint value (last observed post-baseline value). Shifts from baseline to endpoint were summarized using participant counts grouped into three categories: - Low (below normal range) - Normal (within the normal range of 9.4 to 12.5 seconds) - High (above normal range). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Injection Site Reactions</measure>
    <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
    <description>Number of participants who reported treatment-emergent injection site reactions are summarized. Preferred terms from MedDRA version 18.1 were offered without a threshold applied. Injection site reactions included injection site induration, pain, erythema, haemorrhage, pruritus, swelling, bruising, rash, urticaria, warmth, dermatitis, haematoma, inflammation, discolouration, discomfort, hypersensitivity, hypoaesthesia, irritation, oedema, papule, paraesthesia, vesicles and pallor. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)</measure>
    <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
    <description>eC-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. Suicidal behavior was defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period at Month 12</measure>
    <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
    <description>A migraine day was defined as when at least 1 of the following situations occurred: A calendar day(0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for migraine with or without aura; a calendar day(0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day(0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)*28. Change was calculated as post-baseline value - baseline value.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Monthly Average Number of Headache Days of Any Severity During the 4-Week Period at Month 12</measure>
    <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
    <description>Headaches were subjectively rated by participants as mild, moderate or severe. A headache day of any severity for both CM and EM participants was defined as a calendar day (00:00 to 23:59) where the participant (using the electronic headache diary device) reports: a day with headache pain that lasts at least 4 hours with a peak severity of any severity or; a day when the participant used acute migraine-specific medication (triptans or ergots) to treat a headache of any severity or duration. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) * 28. The change was calculated as post-baseline value - baseline value.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With At Least 50% Reduction From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period at Month 12</measure>
    <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
    <description>A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period) * 28.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With At Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 4-Week Period</measure>
    <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
    <description>Headaches were subjectively rated by participants as mild, moderate or severe. A headache day of at least moderate severity for both CM and EM participants was defined as a calendar day (00:00 to 23:59) where the participant (using the electronic headache diary device) reports: a day with headache pain that lasts at least 4 hours with a peak severity of at least moderate severity or; a day when the participant used acute migraine-specific medication (triptans or ergots) to treat a headache of any severity or duration. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) * 28.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1890</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 milligrams (mg) SC as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters [mL] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEV-48125 225 mg Monthly: Active Rollover Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, will receive 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who do not rollover from the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TEV-48125 675 mg Quarterly: Active Rollover Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, will receive fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fremanezumab</intervention_name>
    <description>Fremanezumab will be administered as per the dose and schedule specified in the respective arms.</description>
    <arm_group_label>TEV-48125 225 mg Monthly: Active Rollover Participants</arm_group_label>
    <arm_group_label>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</arm_group_label>
    <arm_group_label>TEV-48125 675 mg Quarterly: Active Rollover Participants</arm_group_label>
    <arm_group_label>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</arm_group_label>
    <other_name>TEV-48125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching to fremanezumab will be administered as per schedule specified in the respective arms.</description>
    <arm_group_label>TEV-48125 225 mg Monthly: Active Rollover Participants</arm_group_label>
    <arm_group_label>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</arm_group_label>
    <arm_group_label>TEV-48125 675 mg Quarterly: Active Rollover Participants</arm_group_label>
    <arm_group_label>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants Rolling Over from the Pivotal Efficacy Studies:

          -  Participant must have signed and dated the informed consent document.

          -  Participant must have completed the pivotal efficacy study without major protocol
             violations.

               -  Additional criteria apply, please contact the investigator for more information.

        Participants Not Rolling Over from the Pivotal Efficacy Studies:

          -  Males or females aged 18 to 70 years, inclusive, with migraine onset at less than or
             equal to (≤) 50 years of age.

          -  Participant signed and dated the informed consent document.

          -  Participant has a history of migraine or clinical judgment suggests a migraine
             diagnosis.

          -  Participant fulfills the criteria for EM or CM with prospectively collected baseline
             information during the 28-day run-in period.

          -  Body mass index (BMI) of 17.5 to 37.5 kilograms/square meter (kg/m^2) and a total body
             weight between 45 and 120 kg, inclusive.

          -  All participants must be of non-childbearing potential.

               1. Participants must simultaneously use 2 forms of highly effective contraception
                  methods.

               2. Participants will remain abstinent throughout the study.

          -  Female participants of childbearing potential must have a negative serum beta-human
             chorionic gonadotropin (β-HCG) pregnancy test prior at screening (confirmed by urine
             dipstick β-HCG pregnancy test at baseline).

          -  The participant must be willing and able to comply with study restrictions, to remain
             at the clinic for the required duration during the study period, and to return to the
             clinic for the follow-up evaluation.

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

        Participants Rolling Over from the Pivotal Efficacy Studies:

          -  Pregnant or nursing females

          -  Compliance with daily diary entry lower than 75 percent (%) at the last month of the
             double-blind treatment period of the pivotal efficacy study.

               -  Additional criteria apply, please contact the investigator for more information.

        Participants Not Rolling Over from the Pivotal Efficacy Studies:

          -  Clinically significant findings at the discretion of the investigator.

          -  Evidence or medical history of clinically significant psychiatric issues, including
             any suicide attempt in the past, or suicidal ideation with a specific plan in the past
             2 years.

          -  History of clinically significant cardiovascular disease or vascular ischemia (such as
             myocardial, neurological [for example; cerebral ischemia], peripheral extremity
             ischemia, or other ischemic event) or thromboembolic events (arterial or venous
             thrombotic or embolic events) such as cerebrovascular accident (including transient
             ischemic attacks), deep vein thrombosis, or pulmonary embolism -Known infection or
             history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C
             infection.

          -  Past or current history of cancer in the past 5 years, except for appropriately
             treated nonmelanoma skin carcinoma.

          -  Pregnant or nursing females.

          -  History of hypersensitivity reactions to injected proteins, including monoclonal
             antibodies.

          -  Participation in a clinical study of a new chemical entity or a prescription medicine
             within 2 months before study drug administration or 5 half-lives, whichever is longer.

          -  History of alcohol or drug abuse during the past 2 years, or alcohol or drug
             dependence during the past 5 years.

          -  The participant cannot participate or successfully complete the study, in the opinion
             of their healthcare provider or the investigator, for any of the following reasons:

               1. mentally or legally incapacitated or unable to give consent for any reason.

               2. in custody due to an administrative or a legal decision, under guardianship, or
                  institutionalized.

               3. unable to be contacted in case of emergency.

               4. has any other condition, which, in the opinion of the investigator, makes the
                  participant inappropriate for inclusion in the study.

          -  Participant is a study center or sponsor employee who is directly involved in the
             study or the relative of such an employee.

               -  Additional criteria apply, please contact the investigator for more information.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>Teva Pharmaceuticals USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Teva Investigational Site 13628</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13577</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13606</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13579</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13602</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13568</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13546</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13540</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13632</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13571</name>
      <address>
        <city>Redondo Beach</city>
        <state>California</state>
        <zip>90277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13573</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13538</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13594</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13595</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13629</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13557</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13593</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13633</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13612</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13631</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13563</name>
      <address>
        <city>East Hartford</city>
        <state>Connecticut</state>
        <zip>06118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13550</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13635</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13597</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13607</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13559</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13584</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13587</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13567</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13553</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13616</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13620</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13537</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13604</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13585</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13621</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60654</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13627</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13596</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13617</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13598</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13566</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13603</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13582</name>
      <address>
        <city>Pikesville</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13590</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13589</name>
      <address>
        <city>New Bedford</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13543</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13539</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13542</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13534</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13619</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13536</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13618</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13605</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13578</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13575</name>
      <address>
        <city>Martinsville</city>
        <state>New Jersey</state>
        <zip>08836</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13622</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13588</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13576</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13565</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13544</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13574</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13545</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13609</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13625</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13634</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13533</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13624</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13569</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13626</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13561</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13601</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13591</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13554</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13608</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13615</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13556</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13560</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13551</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13532</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13552</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13541</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13623</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13611</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13572</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13614</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13581</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13630</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13564</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13586</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 13600</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11124</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11122</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11120</name>
      <address>
        <city>Calgary</city>
        <zip>T3M 1M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11121</name>
      <address>
        <city>Montreal</city>
        <zip>H2W 1V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 11123</name>
      <address>
        <city>Sarnia</city>
        <zip>N7T 4X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54144</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54141</name>
      <address>
        <city>Kunratice</city>
        <zip>14800</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54145</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54142</name>
      <address>
        <city>Prague 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54146</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54143</name>
      <address>
        <city>Praha</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40018</name>
      <address>
        <city>Helsinki</city>
        <zip>00180</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40017</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40016</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80096</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80099</name>
      <address>
        <city>Jerusalem</city>
        <zip>9112001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80098</name>
      <address>
        <city>Nahariya</city>
        <zip>221001</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80097</name>
      <address>
        <city>Netanya</city>
        <zip>4244916</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80100</name>
      <address>
        <city>Ramat Gan</city>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 80095</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84072</name>
      <address>
        <city>Chofu-shi</city>
        <zip>182-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84066</name>
      <address>
        <city>Kagoshima-shi</city>
        <zip>892-0844</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84069</name>
      <address>
        <city>Kai</city>
        <zip>400-0124</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84073</name>
      <address>
        <city>Kawasaki</city>
        <zip>211-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84067</name>
      <address>
        <city>Kyoto</city>
        <zip>600-8811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84062</name>
      <address>
        <city>Osaka-shi</city>
        <zip>556-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84070</name>
      <address>
        <city>Saitama</city>
        <zip>338-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84061</name>
      <address>
        <city>Sendai-shi</city>
        <zip>982-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84063</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84068</name>
      <address>
        <city>Shizuoka</city>
        <zip>4200-853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84065</name>
      <address>
        <city>Tochigi</city>
        <zip>321-0293</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84064</name>
      <address>
        <city>Tokyo</city>
        <zip>182-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 84071</name>
      <address>
        <city>Toyonaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53364</name>
      <address>
        <city>Krakow</city>
        <zip>31-523</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53363</name>
      <address>
        <city>Krakow</city>
        <zip>33-332</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53366</name>
      <address>
        <city>Lublin</city>
        <zip>20-022</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53365</name>
      <address>
        <city>Poznan</city>
        <zip>60-529</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53367</name>
      <address>
        <city>Warsaw</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50399</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50395</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50394</name>
      <address>
        <city>Moscow</city>
        <zip>121467</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50400</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50398</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50396</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <zip>603137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 50397</name>
      <address>
        <city>Ufa</city>
        <zip>450007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31207</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31208</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31205</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31206</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Finland</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2015</study_first_posted>
  <results_first_submitted>June 5, 2019</results_first_submitted>
  <results_first_submitted_qc>August 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2019</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02638103/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02638103/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with chronic or episodic migraine (CM or EM) who completed the pivotal efficacy studies of fremanezumab (TV48125-CNS-30049 [NCT02621931] and TV48125-CNS-30050 [NCT02629861]) and agreed to participate in this study; and new participants meeting eligibility criteria (not rolling over from pivotal studies), were enrolled in this study.</recruitment_details>
      <pre_assignment_details>A total of 1890 participants were enrolled, including 917 participants with CM rolled over from Study TV48125-CNS-30049, 661 participants with EM rolled over from Study TV48125-CNS-30050, and 312 newly enrolled participants (193 with CM and 119 with EM).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
          <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab (TEV-48125) 675 milligrams (mg) subcutaneously (SC) as loading dose (3 injections of fremanezumab 225 mg/1.5 milliliters [mL] on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="P2">
          <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
          <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="P3">
          <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
          <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="P4">
          <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
          <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="419"/>
                <participants group_id="P2" count="526"/>
                <participants group_id="P3" count="420"/>
                <participants group_id="P4" count="525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="418"/>
                <participants group_id="P2" count="526"/>
                <participants group_id="P3" count="419"/>
                <participants group_id="P4" count="525"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="416"/>
                <participants group_id="P2" count="520"/>
                <participants group_id="P3" count="419"/>
                <participants group_id="P4" count="523"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="313"/>
                <participants group_id="P2" count="408"/>
                <participants group_id="P3" count="335"/>
                <participants group_id="P4" count="383"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="118"/>
                <participants group_id="P3" count="85"/>
                <participants group_id="P4" count="142"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="61"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance to Study Procedures</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) analysis set included all participants who were randomized in this study for long-term safety evaluation, regardless if they receive study treatment or not.</population>
      <group_list>
        <group group_id="B1">
          <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
          <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="B2">
          <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
          <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="B3">
          <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
          <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="B4">
          <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
          <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="419"/>
            <count group_id="B2" value="526"/>
            <count group_id="B3" value="420"/>
            <count group_id="B4" value="525"/>
            <count group_id="B5" value="1890"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="12.09"/>
                    <measurement group_id="B2" value="42.9" spread="11.97"/>
                    <measurement group_id="B3" value="44.0" spread="11.67"/>
                    <measurement group_id="B4" value="43.2" spread="11.73"/>
                    <measurement group_id="B5" value="43.5" spread="11.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="365"/>
                    <measurement group_id="B2" value="454"/>
                    <measurement group_id="B3" value="369"/>
                    <measurement group_id="B4" value="457"/>
                    <measurement group_id="B5" value="1645"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="387"/>
                    <measurement group_id="B2" value="481"/>
                    <measurement group_id="B3" value="386"/>
                    <measurement group_id="B4" value="484"/>
                    <measurement group_id="B5" value="1738"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="424"/>
                    <measurement group_id="B3" value="343"/>
                    <measurement group_id="B4" value="412"/>
                    <measurement group_id="B5" value="1530"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="191"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Migraine Days</title>
          <description>A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for migraine with or without aura; a calendar day demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for probable migraine; a calendar day demonstrating a headache of any duration that was treated with migraine-specific medications.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.9" spread="5.99"/>
                    <measurement group_id="B2" value="13.1" spread="5.49"/>
                    <measurement group_id="B3" value="13.6" spread="5.86"/>
                    <measurement group_id="B4" value="13.2" spread="5.26"/>
                    <measurement group_id="B5" value="13.4" spread="5.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Headache Days of Any Severity</title>
          <description>Headaches were subjectively rated by participants as mild, moderate or severe. A headache day of any severity for both CM and EM participants was defined as a calendar day (00:00 to 23:59) where the participant (using the electronic headache diary device) reports: a day with headache pain that lasts at least 4 hours with a peak severity of any severity or; a day when the participant used acute migraine-specific medication (triptans or ergots) to treat a headache of any severity or duration.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.6" spread="6.68"/>
                    <measurement group_id="B2" value="12.7" spread="6.20"/>
                    <measurement group_id="B3" value="13.2" spread="6.32"/>
                    <measurement group_id="B4" value="12.9" spread="6.02"/>
                    <measurement group_id="B5" value="13.1" spread="6.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events (AEs)</title>
        <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE was defined as inability to carry out usual activities. Treatment-related AEs were defined as AEs with possible, probable, definite, or missing relationship to study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
        <time_frame>Baseline (Day 0) up to follow-up visit (Day 533)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs)</title>
          <description>An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severe AE was defined as inability to carry out usual activities. Treatment-related AEs were defined as AEs with possible, probable, definite, or missing relationship to study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="419"/>
                <count group_id="O4" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365"/>
                    <measurement group_id="O2" value="456"/>
                    <measurement group_id="O3" value="365"/>
                    <measurement group_id="O4" value="426"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="45"/>
                    <measurement group_id="O4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                    <measurement group_id="O2" value="288"/>
                    <measurement group_id="O3" value="242"/>
                    <measurement group_id="O4" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation from study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period at Month 12</title>
        <description>A migraine day was defined as when at least 1 of the following situations occurred: A calendar day(0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for migraine with or without aura; a calendar day(0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day(0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)*28. Change was calculated as post-baseline value - baseline value.</description>
        <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
        <population>Full analysis set (FAS):all participants who received at least 1 dose of fremanezumab, had at least 10 days of efficacy assessments by e-diary after first injection for this study. Data for this outcome was collected and reported separately for CM and EM participants.‘Overall number of participants analyzed'=participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675mg Quarterly:New/Placebo Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O5">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O6">
            <title>TEV-48125 225 mg Monthly: Active Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O7">
            <title>TEV-48125 675mg Quarterly:New/Placebo Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O8">
            <title>TEV-48125 675 mg Quarterly: Active Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period at Month 12</title>
          <description>A migraine day was defined as when at least 1 of the following situations occurred: A calendar day(0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for migraine with or without aura; a calendar day(0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day(0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period)*28. Change was calculated as post-baseline value - baseline value.</description>
          <population>Full analysis set (FAS):all participants who received at least 1 dose of fremanezumab, had at least 10 days of efficacy assessments by e-diary after first injection for this study. Data for this outcome was collected and reported separately for CM and EM participants.‘Overall number of participants analyzed'=participants evaluable for this outcome.</population>
          <units>days/month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="230"/>
                <count group_id="O5" value="124"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="138"/>
                <count group_id="O8" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="6.98"/>
                    <measurement group_id="O2" value="-8.2" spread="6.14"/>
                    <measurement group_id="O3" value="-7.6" spread="6.87"/>
                    <measurement group_id="O4" value="-7.0" spread="6.54"/>
                    <measurement group_id="O5" value="-4.5" spread="4.20"/>
                    <measurement group_id="O6" value="-5.5" spread="4.01"/>
                    <measurement group_id="O7" value="-5.5" spread="3.65"/>
                    <measurement group_id="O8" value="-5.0" spread="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Monthly Average Number of Headache Days of Any Severity During the 4-Week Period at Month 12</title>
        <description>Headaches were subjectively rated by participants as mild, moderate or severe. A headache day of any severity for both CM and EM participants was defined as a calendar day (00:00 to 23:59) where the participant (using the electronic headache diary device) reports: a day with headache pain that lasts at least 4 hours with a peak severity of any severity or; a day when the participant used acute migraine-specific medication (triptans or ergots) to treat a headache of any severity or duration. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) * 28. The change was calculated as post-baseline value - baseline value.</description>
        <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
        <population>FAS: all participants who received at least 1 dose of fremanezumab, and had at least 10 days of efficacy assessments by electronic diary after first injection for this study. Data for this outcome was collected and reported separately for CM and EM participants. ‘Overall number of participants analyzed' = participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675mg Quarterly:New/Placebo Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O5">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O6">
            <title>TEV-48125 225 mg Monthly: Active Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O7">
            <title>TEV-48125 675mg Quarterly:New/Placebo Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O8">
            <title>TEV-48125 675 mg Quarterly: Active Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Monthly Average Number of Headache Days of Any Severity During the 4-Week Period at Month 12</title>
          <description>Headaches were subjectively rated by participants as mild, moderate or severe. A headache day of any severity for both CM and EM participants was defined as a calendar day (00:00 to 23:59) where the participant (using the electronic headache diary device) reports: a day with headache pain that lasts at least 4 hours with a peak severity of any severity or; a day when the participant used acute migraine-specific medication (triptans or ergots) to treat a headache of any severity or duration. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) * 28. The change was calculated as post-baseline value - baseline value.</description>
          <population>FAS: all participants who received at least 1 dose of fremanezumab, and had at least 10 days of efficacy assessments by electronic diary after first injection for this study. Data for this outcome was collected and reported separately for CM and EM participants. ‘Overall number of participants analyzed' = participants evaluable for this outcome.</population>
          <units>days/month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="192"/>
                <count group_id="O2" value="233"/>
                <count group_id="O3" value="194"/>
                <count group_id="O4" value="230"/>
                <count group_id="O5" value="124"/>
                <count group_id="O6" value="173"/>
                <count group_id="O7" value="138"/>
                <count group_id="O8" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.7" spread="6.79"/>
                    <measurement group_id="O2" value="-7.9" spread="6.01"/>
                    <measurement group_id="O3" value="-7.2" spread="6.48"/>
                    <measurement group_id="O4" value="-7.1" spread="6.88"/>
                    <measurement group_id="O5" value="-4.4" spread="4.25"/>
                    <measurement group_id="O6" value="-5.0" spread="3.90"/>
                    <measurement group_id="O7" value="-5.0" spread="3.63"/>
                    <measurement group_id="O8" value="-4.8" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results</title>
        <description>Potentially clinically significant abnormal serum chemistry findings included: Blood Urea Nitrogen (BUN): greater than or equal to (&gt;=) 10.71 millimoles/liter (mmol/L), creatinine: &gt;=177 micromoles/liter (µmol/L), bilirubin: &gt;=34.2 µmol/L, Alanine Aminotransferase (ALT) (units/liter [U/L]): &gt;=3*upper limit of normal (ULN) Aspartate Aminotransferase (AST) (U/L): &gt;=3*ULN, and Gamma Glutamyl Transferase (GGT) (U/L): &gt;=3*ULN. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
        <time_frame>Baseline (Day 0) up to end of treatment (EOT) visit (Day 336)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed'=participants with both baseline and post-baseline serum chemistry values.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Abnormal Serum Chemistry Results</title>
          <description>Potentially clinically significant abnormal serum chemistry findings included: Blood Urea Nitrogen (BUN): greater than or equal to (&gt;=) 10.71 millimoles/liter (mmol/L), creatinine: &gt;=177 micromoles/liter (µmol/L), bilirubin: &gt;=34.2 µmol/L, Alanine Aminotransferase (ALT) (units/liter [U/L]): &gt;=3*upper limit of normal (ULN) Aspartate Aminotransferase (AST) (U/L): &gt;=3*ULN, and Gamma Glutamyl Transferase (GGT) (U/L): &gt;=3*ULN. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed'=participants with both baseline and post-baseline serum chemistry values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="518"/>
                <count group_id="O3" value="412"/>
                <count group_id="O4" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Abnormal Hematology Results</title>
        <description>Potentially clinically significant abnormal hematology findings included: hemoglobin: less than (&lt;) 115 grams/liter (g/L) (in males) or less than or equal to (&lt;=) 95 g/L (in females), hematocrit: &lt;0.37 L/L (in male) or &lt;0.32 L/L (in female), leukocytes: &gt;=20*10^9/L or &lt;=3*10^9/L, eosinophils/leukocytes: &gt;=10%, and platelets: &gt;=700*10^9/L or &lt;=75*10^9/L. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
        <time_frame>Baseline (Day 0) up to EOT visit (Day 336)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed'=participants with both baseline and post-baseline hematology parameter values.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Abnormal Hematology Results</title>
          <description>Potentially clinically significant abnormal hematology findings included: hemoglobin: less than (&lt;) 115 grams/liter (g/L) (in males) or less than or equal to (&lt;=) 95 g/L (in females), hematocrit: &lt;0.37 L/L (in male) or &lt;0.32 L/L (in female), leukocytes: &gt;=20*10^9/L or &lt;=3*10^9/L, eosinophils/leukocytes: &gt;=10%, and platelets: &gt;=700*10^9/L or &lt;=75*10^9/L. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed'=participants with both baseline and post-baseline hematology parameter values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="518"/>
                <count group_id="O3" value="412"/>
                <count group_id="O4" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results</title>
        <description>Potentially clinically significant abnormal urinalysis findings included: blood: &gt;=2 unit increase from baseline, urine glucose (milligrams/decilitre [mg/dL]): &gt;=2 unit increase from baseline, ketones (mg/dL): &gt;=2 unit increase from baseline, urine protein (mg/dL): &gt;=2 unit increase from baseline. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
        <time_frame>Baseline (Day 0) up to EOT visit (Day 336)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed'=participants with both baseline and post-baseline urinalysis values.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Abnormal Urinalysis Laboratory Tests Results</title>
          <description>Potentially clinically significant abnormal urinalysis findings included: blood: &gt;=2 unit increase from baseline, urine glucose (milligrams/decilitre [mg/dL]): &gt;=2 unit increase from baseline, ketones (mg/dL): &gt;=2 unit increase from baseline, urine protein (mg/dL): &gt;=2 unit increase from baseline. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed'=participants with both baseline and post-baseline urinalysis values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="408"/>
                <count group_id="O2" value="517"/>
                <count group_id="O3" value="412"/>
                <count group_id="O4" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="170"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values</title>
        <description>Potentially clinically significant abnormal vital signs findings included: pulse rate: &lt;=50 beats/minute (bpm) and decrease of &gt;=15 bpm, or &gt;=120 bpm and increase of &gt;=15 bpm; systolic blood pressure: &lt;=90 millimeters of mercury (mmHg) and decrease of &gt;=20 mmHg, or &gt;=180 mmHg and increase of &gt;=20 mmHg; diastolic blood pressure: &lt;=50 mmHg and decrease of &gt;=15 mmHg or &gt;=105 mmHg and increase of &gt;=15 mmHg; respiratory rate: &lt;10 breaths/minute; and body temperature &gt;=38.3 degrees centigrade and change of &gt;=1.1 degrees centigrade. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
        <time_frame>Baseline (Day 0) up to EOT visit (Day 336)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed'=participants with both baseline and post-baseline vital signs values.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially Clinically Significant Abnormal Vital Signs Values</title>
          <description>Potentially clinically significant abnormal vital signs findings included: pulse rate: &lt;=50 beats/minute (bpm) and decrease of &gt;=15 bpm, or &gt;=120 bpm and increase of &gt;=15 bpm; systolic blood pressure: &lt;=90 millimeters of mercury (mmHg) and decrease of &gt;=20 mmHg, or &gt;=180 mmHg and increase of &gt;=20 mmHg; diastolic blood pressure: &lt;=50 mmHg and decrease of &gt;=15 mmHg or &gt;=105 mmHg and increase of &gt;=15 mmHg; respiratory rate: &lt;10 breaths/minute; and body temperature &gt;=38.3 degrees centigrade and change of &gt;=1.1 degrees centigrade. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed'=participants with both baseline and post-baseline vital signs values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="415"/>
                <count group_id="O2" value="520"/>
                <count group_id="O3" value="414"/>
                <count group_id="O4" value="519"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters</title>
        <description>ECG parameters included: heart rate, PR interval, QRS interval, QT interval corrected using the Fridericia formula (QTcF), QT interval corrected using the Bazett's formula (QTcB) and RR interval. Shifts represented as Baseline - endpoint value (last observed post-baseline value). Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
        <time_frame>Baseline (Day 0), endpoint (Day 336)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed' = participants with both baseline and endpoint electrocardiogram findings.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shift From Baseline to Endpoint in Electrocardiogram (ECG) Parameters</title>
          <description>ECG parameters included: heart rate, PR interval, QRS interval, QT interval corrected using the Fridericia formula (QTcF), QT interval corrected using the Bazett's formula (QTcB) and RR interval. Shifts represented as Baseline - endpoint value (last observed post-baseline value). Abnormal NCS indicated an abnormal but not clinically significant finding. Abnormal CS indicated an abnormal and clinically significant finding. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed' = participants with both baseline and endpoint electrocardiogram findings.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="386"/>
                <count group_id="O2" value="492"/>
                <count group_id="O3" value="391"/>
                <count group_id="O4" value="489"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal - Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="295"/>
                    <measurement group_id="O3" value="230"/>
                    <measurement group_id="O4" value="296"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal - Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal - Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal NCS - Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal NCS - Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="69"/>
                    <measurement group_id="O4" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal NCS - Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal CS - Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal CS - Abnormal NCS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal CS - Abnormal CS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shift From Baseline to Endpoint in Coagulation Laboratory Test Results</title>
        <description>Coagulation parameters included: prothrombin time (PT) (seconds), prothrombin international normalized ratio (INR), activated partial thromboplastin time (aPTT) (seconds). Shifts represented as Baseline - endpoint value (last observed post-baseline value). Shifts from baseline to endpoint were summarized using participant counts grouped into three categories: - Low (below normal range) - Normal (within the normal range of 9.4 to 12.5 seconds) - High (above normal range). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
        <time_frame>Baseline (Day 0), endpoint (Day 336)</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed' = participants with both baseline and endpoint coagulation laboratory test results. 'Number analyzed' = participants evaluable for specified categories.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shift From Baseline to Endpoint in Coagulation Laboratory Test Results</title>
          <description>Coagulation parameters included: prothrombin time (PT) (seconds), prothrombin international normalized ratio (INR), activated partial thromboplastin time (aPTT) (seconds). Shifts represented as Baseline - endpoint value (last observed post-baseline value). Shifts from baseline to endpoint were summarized using participant counts grouped into three categories: - Low (below normal range) - Normal (within the normal range of 9.4 to 12.5 seconds) - High (above normal range). A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab. Here, 'Overall number of participants analyzed' = participants with both baseline and endpoint coagulation laboratory test results. 'Number analyzed' = participants evaluable for specified categories.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="516"/>
                <count group_id="O3" value="410"/>
                <count group_id="O4" value="513"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="516"/>
                    <count group_id="O3" value="410"/>
                    <count group_id="O4" value="513"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Low-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="370"/>
                    <measurement group_id="O2" value="465"/>
                    <measurement group_id="O3" value="374"/>
                    <measurement group_id="O4" value="451"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prothrombin INR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="516"/>
                    <count group_id="O3" value="410"/>
                    <count group_id="O4" value="513"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Low-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="468"/>
                    <measurement group_id="O3" value="372"/>
                    <measurement group_id="O4" value="472"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>aPTT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="516"/>
                    <count group_id="O3" value="410"/>
                    <count group_id="O4" value="513"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Low-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Low-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="341"/>
                    <measurement group_id="O2" value="423"/>
                    <measurement group_id="O3" value="334"/>
                    <measurement group_id="O4" value="414"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High-High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With At Least 50% Reduction From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period at Month 12</title>
        <description>A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period) * 28.</description>
        <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
        <population>FAS: all participants who received at least 1 dose of fremanezumab, and had at least 10 days of efficacy assessments by electronic diary after first injection for this study. Data for this outcome was collected and reported separately for CM and EM participants. ‘Overall number of participants analyzed' = participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675mg Quarterly:New/Placebo Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O5">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O6">
            <title>TEV-48125 225 mg Monthly: Active Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O7">
            <title>TEV-48125 675mg Quarterly:New/Placebo Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O8">
            <title>TEV-48125 675 mg Quarterly: Active Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 50% Reduction From Baseline in Monthly Average Number of Migraine Days During the 4-Week Period at Month 12</title>
          <description>A migraine day was defined as when at least 1 of the following situations occurred: A calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for migraine with or without aura; a calendar day (0:00 to 23:59) demonstrating at least 4 consecutive hours (for CM participants) or at least 2 consecutive hours (for EM participants) of a headache meeting criteria for probable migraine, a migraine subtype where only 1 migraine criterion was missing; a calendar day (0:00 to 23:59) demonstrating a headache of any duration that was treated with migraine-specific medications (triptans and ergot compounds). Monthly averages were derived and normalized to 28 days equivalent by formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in e-diary over relevant period) * 28.</description>
          <population>FAS: all participants who received at least 1 dose of fremanezumab, and had at least 10 days of efficacy assessments by electronic diary after first injection for this study. Data for this outcome was collected and reported separately for CM and EM participants. ‘Overall number of participants analyzed' = participants evaluable for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="195"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="237"/>
                <count group_id="O5" value="125"/>
                <count group_id="O6" value="174"/>
                <count group_id="O7" value="139"/>
                <count group_id="O8" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="75"/>
                    <measurement group_id="O7" value="68"/>
                    <measurement group_id="O8" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With At Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 4-Week Period</title>
        <description>Headaches were subjectively rated by participants as mild, moderate or severe. A headache day of at least moderate severity for both CM and EM participants was defined as a calendar day (00:00 to 23:59) where the participant (using the electronic headache diary device) reports: a day with headache pain that lasts at least 4 hours with a peak severity of at least moderate severity or; a day when the participant used acute migraine-specific medication (triptans or ergots) to treat a headache of any severity or duration. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) * 28.</description>
        <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
        <population>FAS: all participants who received at least 1 dose of fremanezumab, and had at least 10 days of efficacy assessments by electronic diary after first injection for this study. Data for this outcome was collected and reported separately for CM and EM participants. ‘Overall number of participants analyzed' = participants evaluable for this outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675mg Quarterly:New/Placebo Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover CM Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O5">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O6">
            <title>TEV-48125 225 mg Monthly: Active Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O7">
            <title>TEV-48125 675mg Quarterly:New/Placebo Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
          <group group_id="O8">
            <title>TEV-48125 675 mg Quarterly: Active Rollover EM Participants</title>
            <description>Participants with EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 4-Week Period</title>
          <description>Headaches were subjectively rated by participants as mild, moderate or severe. A headache day of at least moderate severity for both CM and EM participants was defined as a calendar day (00:00 to 23:59) where the participant (using the electronic headache diary device) reports: a day with headache pain that lasts at least 4 hours with a peak severity of at least moderate severity or; a day when the participant used acute migraine-specific medication (triptans or ergots) to treat a headache of any severity or duration. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) * 28.</description>
          <population>FAS: all participants who received at least 1 dose of fremanezumab, and had at least 10 days of efficacy assessments by electronic diary after first injection for this study. Data for this outcome was collected and reported separately for CM and EM participants. ‘Overall number of participants analyzed' = participants evaluable for this outcome.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="240"/>
                <count group_id="O3" value="197"/>
                <count group_id="O4" value="237"/>
                <count group_id="O5" value="124"/>
                <count group_id="O6" value="174"/>
                <count group_id="O7" value="138"/>
                <count group_id="O8" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="62"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="58"/>
                    <measurement group_id="O6" value="72"/>
                    <measurement group_id="O7" value="67"/>
                    <measurement group_id="O8" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Injection Site Reactions</title>
        <description>Number of participants who reported treatment-emergent injection site reactions are summarized. Preferred terms from MedDRA version 18.1 were offered without a threshold applied. Injection site reactions included injection site induration, pain, erythema, haemorrhage, pruritus, swelling, bruising, rash, urticaria, warmth, dermatitis, haematoma, inflammation, discolouration, discomfort, hypersensitivity, hypoaesthesia, irritation, oedema, papule, paraesthesia, vesicles and pallor. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
        <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Injection Site Reactions</title>
          <description>Number of participants who reported treatment-emergent injection site reactions are summarized. Preferred terms from MedDRA version 18.1 were offered without a threshold applied. Injection site reactions included injection site induration, pain, erythema, haemorrhage, pruritus, swelling, bruising, rash, urticaria, warmth, dermatitis, haematoma, inflammation, discolouration, discomfort, hypersensitivity, hypoaesthesia, irritation, oedema, papule, paraesthesia, vesicles and pallor. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="419"/>
                <count group_id="O4" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="174"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="156"/>
                    <measurement group_id="O3" value="135"/>
                    <measurement group_id="O4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="99"/>
                    <measurement group_id="O4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="21"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pruritus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site warmth</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site dermatitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site haematoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site discolouration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site hypersensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site hypoaesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site oedema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site papule</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site paraesthesia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site vesicles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site pallor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)</title>
        <description>eC-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. Suicidal behavior was defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent.</description>
        <time_frame>Baseline (Day -28 to Day -1), Month 12</time_frame>
        <population>Safety population included all participants who received at least 1 dose of fremanezumab.</population>
        <group_list>
          <group group_id="O1">
            <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
            <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O2">
            <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
            <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O3">
            <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
          <group group_id="O4">
            <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
            <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suicidal Ideation and Suicidal Behavior as Assessed by the Electronic Columbia-Suicide Severity Rating Scale (eC-SSRS)</title>
          <description>eC-SSRS is a questionnaire to assess suicidal ideation and suicidal behavior. Suicidal behavior was defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation was defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent, any self-injurious behavior with no suicidal intent.</description>
          <population>Safety population included all participants who received at least 1 dose of fremanezumab.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="526"/>
                <count group_id="O3" value="419"/>
                <count group_id="O4" value="525"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 0) up to follow-up visit (Day 533)</time_frame>
      <desc>Safety population included all participants who received at least 1 dose of fremanezumab.</desc>
      <group_list>
        <group group_id="E1">
          <title>TEV-48125 225 mg Monthly: New/Placebo Rollover Participants</title>
          <description>Participants with CM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="E2">
          <title>TEV-48125 225 mg Monthly: Active Rollover Participants</title>
          <description>Participants with CM who were randomized to the active treatment group (Fremanezumab 675/225 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC as loading dose (3 injections of fremanezumab 225 mg/1.5 mL on Day 0) followed by 11 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308). Participants with EM who were randomized to the active treatment group (Fremanezumab 225 mg) in the pivotal efficacy study, received 12 monthly SC doses of fremanezumab at 225 mg (1 injection of fremanezumab 225 mg/1.5 mL and 2 injections of placebo 1.5 mL on Days 0, 84, 168, and 252; and 1 injection of fremanezumab 225 mg/1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="E3">
          <title>TEV-48125 675 mg Quarterly: New/Placebo Rollover Participants</title>
          <description>Participants with CM or EM who were randomized to the placebo treatment group or participants who did not rollover from the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
        <group group_id="E4">
          <title>TEV-48125 675 mg Quarterly: Active Rollover Participants</title>
          <description>Participants with CM or EM who were randomized to the active treatment group (Fremanezumab 675 mg) in the pivotal efficacy study, received fremanezumab 675 mg SC once every 3 months for 12 months for a total of 4 doses (3 injections of fremanezumab 225 mg/1.5 mL on Days 0, 84, 168, and 252; and 1 injection of placebo 1.5 mL on Days 28, 56, 112, 140, 196, 224, 280, and 308).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="418"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="419"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cerebrovascular arteriovenous malformation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Congenital cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Congenital cystic disease of liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hereditary haemochromatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Ileal stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Petrositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Ammonia increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Vertebral osteophyte</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="526"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Breast cancer stage III</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>High grade B-cell lymphoma Burkitt-like lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Phyllodes tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pituitary tumour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <description>This is a gender-specific AE. Only male participants were at risk.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="68"/>
              </event>
              <event>
                <sub_title>Superficial spreading melanoma stage unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Perineurial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Primary progressive multiple sclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Status migrainosus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Premature separation of placenta</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder with mixed disturbance of emotion and conduct</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Haemorrhagic ovarian cyst</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="454"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Ovarian mass</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="454"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <description>This is a gender-specific AE. Only female participants were at risk.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="457"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="369"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="457"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Lung consolidation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Salpingo-oophorectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="526"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="526"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="419"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="300" subjects_at_risk="418"/>
                <counts group_id="E2" subjects_affected="367" subjects_at_risk="526"/>
                <counts group_id="E3" subjects_affected="284" subjects_at_risk="419"/>
                <counts group_id="E4" subjects_affected="329" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="430" subjects_affected="130" subjects_at_risk="418"/>
                <counts group_id="E2" events="446" subjects_affected="144" subjects_at_risk="526"/>
                <counts group_id="E3" events="284" subjects_affected="99" subjects_at_risk="419"/>
                <counts group_id="E4" events="386" subjects_affected="124" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="43" subjects_affected="34" subjects_at_risk="418"/>
                <counts group_id="E2" events="66" subjects_affected="38" subjects_at_risk="526"/>
                <counts group_id="E3" events="38" subjects_affected="21" subjects_at_risk="419"/>
                <counts group_id="E4" events="62" subjects_affected="38" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="717" subjects_affected="167" subjects_at_risk="418"/>
                <counts group_id="E2" events="753" subjects_affected="174" subjects_at_risk="526"/>
                <counts group_id="E3" events="543" subjects_affected="144" subjects_at_risk="419"/>
                <counts group_id="E4" events="666" subjects_affected="134" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="980" subjects_affected="149" subjects_at_risk="418"/>
                <counts group_id="E2" events="982" subjects_affected="156" subjects_at_risk="526"/>
                <counts group_id="E3" events="981" subjects_affected="135" subjects_at_risk="419"/>
                <counts group_id="E4" events="811" subjects_affected="140" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="101" subjects_affected="31" subjects_at_risk="418"/>
                <counts group_id="E2" events="107" subjects_affected="43" subjects_at_risk="526"/>
                <counts group_id="E3" events="64" subjects_affected="17" subjects_at_risk="419"/>
                <counts group_id="E4" events="64" subjects_affected="24" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="418"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="526"/>
                <counts group_id="E3" events="22" subjects_affected="20" subjects_at_risk="419"/>
                <counts group_id="E4" events="26" subjects_affected="24" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="418"/>
                <counts group_id="E2" events="29" subjects_affected="27" subjects_at_risk="526"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="419"/>
                <counts group_id="E4" events="28" subjects_affected="25" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="61" subjects_affected="43" subjects_at_risk="418"/>
                <counts group_id="E2" events="107" subjects_affected="69" subjects_at_risk="526"/>
                <counts group_id="E3" events="58" subjects_affected="37" subjects_at_risk="419"/>
                <counts group_id="E4" events="108" subjects_affected="68" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="40" subjects_affected="30" subjects_at_risk="418"/>
                <counts group_id="E2" events="28" subjects_affected="27" subjects_at_risk="526"/>
                <counts group_id="E3" events="35" subjects_affected="28" subjects_at_risk="419"/>
                <counts group_id="E4" events="38" subjects_affected="31" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="65" subjects_affected="55" subjects_at_risk="418"/>
                <counts group_id="E2" events="76" subjects_affected="62" subjects_at_risk="526"/>
                <counts group_id="E3" events="97" subjects_affected="73" subjects_at_risk="419"/>
                <counts group_id="E4" events="78" subjects_affected="63" subjects_at_risk="525"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="38" subjects_affected="25" subjects_at_risk="418"/>
                <counts group_id="E2" events="43" subjects_affected="27" subjects_at_risk="526"/>
                <counts group_id="E3" events="29" subjects_affected="26" subjects_at_risk="419"/>
                <counts group_id="E4" events="37" subjects_affected="33" subjects_at_risk="525"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor’s review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor’s designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research</name_or_title>
      <organization>Teva Branded Pharmaceutical Products, R&amp;D Inc.</organization>
      <phone>1-888-483-8279</phone>
      <email>USMedInfo@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

